Amplified Sciences

Amplified Sciences is a private, clinical-stage diagnostics company leveraging a proprietary ultra-sensitive optical reporter platform to create a new class of multi-omics diagnostic tests. Its lead program, PanCystPro™, is a diagnostic test designed to analyze pancreatic cyst fluid to stratify cancer risk in patients with pancreatic cystic lesions, addressing a critical unmet need in early pancreatic cancer detection. The company is positioned in the high-growth molecular diagnostics market, aiming to provide clinicians with tools for more accurate and earlier intervention in debilitating diseases. As a pre-revenue entity, its near-term focus is on clinical validation and commercial preparation for its lead assay.

Proprietary ultra-sensitive universal optical reporter platform enabling multi-omics diagnostic tests, including novel protease turnover multianalyte assays.

Competes with other companies developing molecular tests for pancreatic cyst fluid (e.g., Interpace Biosciences) and faces potential competition from large, diversified diagnostic firms. Its differentiation lies in its focus on measuring protease activity, not just biomarker presence, which may offer improved clinical performance.